The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > ORGANIZATION
ORGANIZATION
- JMA Pres. Yokokura Voices Opposition to Proposed Mixed Care System, Annual Drug Price Revisions
April 21, 2014
- Membership Suspension Appropriate for Novartis Pharma Involvement in SIGN Trial: JPMA
April 21, 2014
- Dainippon’s Takada to Head JPMA Public Affairs Committee
April 18, 2014
- EFPIA Poised to Present Plan for Japan-Version IMI by Year-End
April 16, 2014
- Funding for Investigator-Led Studies Should Be Based on Contracts: EFPIA Japan
April 16, 2014
- More Clinical Trial Sites Sharing Information Online: JMACCT
April 16, 2014
- NCVC Establishes Integrated Information Center to Collect Information on Cardiovascular Diseases from Around the Country
April 16, 2014
- APAC Agrees to Aim for Mutual Recognition of New Drug Review Results by 2020
April 15, 2014
- Sales by 24 Member Companies Total 136.8 Billion Yen in 2013, with 12,361 Employees: JCROA
April 15, 2014
- Rattled Confidence, Dubious Eyes on Doctors “Unfortunate”: JMA Veep
April 11, 2014
- Number of CMRs Growing Rapidly in Anticipation of Major New Product Launches: JSCOA
April 11, 2014
- DSP Pres. Tada Likely to Head JPMA, Astellas’ Hatanaka Tipped for Chief Veep
April 10, 2014
- JPMA Suspends Veep Hasegawa’s Duties for 6 Months over CASE-J
April 4, 2014
- OPMA Appoints MTPC President Tsuchiya, Three Others as New Vice Chairmen
April 2, 2014
- JPMA to Ban Drug Makers from Giving Grants for Clinical Research on Own Products
March 28, 2014
- Funding Disclosures by 5 More FPMAJ Trade Groups to Get Underway in FY2014
March 27, 2014
- JPMA Reinstates Nihon Pharmaceutical Membership after 1-Year Suspension
March 25, 2014
- GHIT Fund Announces New Grants to Develop Treatments for Tropical Diseases, Novel Tuberculosis Vaccine
March 24, 2014
- JPMA Urges Takeda to Improve Promotion Regime over CASE-J
March 24, 2014
- Japanese Drug Makers Conduct MRCTs in More Countries, but Japan Ranks Just 24th as Trial Location: JPMA Survey
March 18, 2014
ページ
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…